LU84893A1 - Composition pharmaceutique - Google Patents
Composition pharmaceutique Download PDFInfo
- Publication number
- LU84893A1 LU84893A1 LU84893A LU84893A LU84893A1 LU 84893 A1 LU84893 A1 LU 84893A1 LU 84893 A LU84893 A LU 84893A LU 84893 A LU84893 A LU 84893A LU 84893 A1 LU84893 A1 LU 84893A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- ointment
- lanolin
- paraffin
- base
- active ingredient
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title description 3
- 235000019388 lanolin Nutrition 0.000 claims description 44
- 239000004166 Lanolin Substances 0.000 claims description 40
- 229940039717 lanolin Drugs 0.000 claims description 39
- 239000002674 ointment Substances 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 13
- 239000012188 paraffin wax Substances 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 12
- 239000003883 ointment base Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 229940057995 liquid paraffin Drugs 0.000 claims description 8
- 239000000470 constituent Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical group O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 2
- 241000928106 Alain Species 0.000 claims 1
- 230000003266 anti-allergic effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002585 base Substances 0.000 description 12
- 239000003885 eye ointment Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 229940069265 ophthalmic ointment Drugs 0.000 description 7
- 206010010741 Conjunctivitis Diseases 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 5
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 206010023332 keratitis Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- AHOWSDUPGJRPTJ-UHFFFAOYSA-N 5-[1-(2-carboxy-4-oxochromen-5-yl)oxy-2-hydroxypropoxy]-4-oxochromene-2-carboxylic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OC(C(O)C)OC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 AHOWSDUPGJRPTJ-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229940048299 acetylated lanolin alcohols Drugs 0.000 description 2
- -1 alkali metal salt Chemical class 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
- AXDIZEFUMZZNES-UHFFFAOYSA-N 5-[3-(2-carboxy-4-oxochromen-5-yl)-3-hydroxypropyl]-4-oxochromene-2-carboxylic acid Chemical compound C(=O)(O)C=1OC2=CC=CC(=C2C(C=1)=O)C(CCC1=C2C(C=C(OC2=CC=C1)C(=O)O)=O)O AXDIZEFUMZZNES-UHFFFAOYSA-N 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940031955 anhydrous lanolin Drugs 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 229940099367 lanolin alcohols Drugs 0.000 description 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8219185 | 1982-07-02 | ||
| GB8219185 | 1982-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU84893A1 true LU84893A1 (fr) | 1983-11-23 |
Family
ID=10531439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU84893A LU84893A1 (fr) | 1982-07-02 | 1983-07-01 | Composition pharmaceutique |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US4526899A (cs) |
| EP (1) | EP0100592B1 (cs) |
| JP (1) | JPS5927814A (cs) |
| AU (1) | AU553272B2 (cs) |
| BE (1) | BE897199A (cs) |
| CA (1) | CA1212322A (cs) |
| CH (1) | CH657776A5 (cs) |
| DE (1) | DE3375640D1 (cs) |
| FR (1) | FR2529457B1 (cs) |
| IE (1) | IE55207B1 (cs) |
| IL (1) | IL69094A (cs) |
| LU (1) | LU84893A1 (cs) |
| NZ (1) | NZ204786A (cs) |
| ZA (1) | ZA834770B (cs) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA927277B (en) * | 1991-10-02 | 1993-05-19 | Boston Ocular Res | Dry eye treatment process and solution. |
| US5698533A (en) * | 1994-07-26 | 1997-12-16 | Kang; Meng-Che | Ophthalmic pharmaceutical composition |
| RU2202338C2 (ru) * | 2001-05-11 | 2003-04-20 | Государственное предприятие Казанское производственное химико-фармацевтическое объединение "Татхимфармпрепараты" | Способ промышленного производства стабильных фармацевтических мазевых композиций |
| US6596284B1 (en) | 2002-04-30 | 2003-07-22 | Thomas E. Fleming | Treating eczema with a combination of isotonic saline ocean® and nasal mast cell stabilizers |
| WO2005003111A1 (ja) * | 2003-07-04 | 2005-01-13 | Astellas Pharma Inc. | ウィルス性結膜炎の予防または治療剤 |
| US20080299182A1 (en) * | 2007-03-01 | 2008-12-04 | Shuyuan Zhang | Methods and formulations for topical gene therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2725334A (en) * | 1951-11-20 | 1955-11-29 | American Cholesterol Products | Modified lanolin |
| DE2023786B2 (de) * | 1970-05-15 | 1973-03-01 | Wasser-in-oel-emulgatoren | |
| GB1537047A (en) * | 1975-10-03 | 1978-12-29 | Fisons Ltd | Eye ointment |
| DE2634908A1 (de) * | 1974-11-09 | 1977-04-14 | Fisons Ltd | Mittel zur behandlung chronischer haut- oder augenerkrankungen |
| US4401663A (en) * | 1981-06-30 | 1983-08-30 | The Procter & Gamble Company | Novel sulfonamide derivatives |
| US4424205A (en) * | 1982-03-18 | 1984-01-03 | The Procter & Gamble Company | Hydroxyphenylacetamides having analgesic and anti-irritant activity |
-
1983
- 1983-06-14 DE DE8383303425T patent/DE3375640D1/de not_active Expired
- 1983-06-14 EP EP83303425A patent/EP0100592B1/en not_active Expired
- 1983-06-20 US US06/505,984 patent/US4526899A/en not_active Expired - Lifetime
- 1983-06-27 CH CH3511/83A patent/CH657776A5/fr not_active IP Right Cessation
- 1983-06-27 CA CA000431222A patent/CA1212322A/en not_active Expired
- 1983-06-28 IL IL69094A patent/IL69094A/xx not_active IP Right Cessation
- 1983-06-29 ZA ZA834770A patent/ZA834770B/xx unknown
- 1983-06-29 AU AU16377/83A patent/AU553272B2/en not_active Ceased
- 1983-07-01 FR FR8311031A patent/FR2529457B1/fr not_active Expired
- 1983-07-01 BE BE0/211109A patent/BE897199A/fr not_active IP Right Cessation
- 1983-07-01 NZ NZ204786A patent/NZ204786A/xx unknown
- 1983-07-01 JP JP58118377A patent/JPS5927814A/ja active Granted
- 1983-07-01 LU LU84893A patent/LU84893A1/fr unknown
- 1983-07-01 IE IE1551/83A patent/IE55207B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0536410B2 (cs) | 1993-05-31 |
| NZ204786A (en) | 1986-06-11 |
| IE55207B1 (en) | 1990-07-04 |
| BE897199A (fr) | 1984-01-02 |
| IL69094A0 (en) | 1983-10-31 |
| US4526899A (en) | 1985-07-02 |
| IL69094A (en) | 1987-02-27 |
| FR2529457B1 (fr) | 1986-05-30 |
| ZA834770B (en) | 1984-04-25 |
| AU553272B2 (en) | 1986-07-10 |
| CA1212322A (en) | 1986-10-07 |
| IE831551L (en) | 1984-01-02 |
| AU1637783A (en) | 1984-01-05 |
| FR2529457A1 (fr) | 1984-01-06 |
| CH657776A5 (fr) | 1986-09-30 |
| DE3375640D1 (en) | 1988-03-17 |
| JPS5927814A (ja) | 1984-02-14 |
| EP0100592A1 (en) | 1984-02-15 |
| EP0100592B1 (en) | 1988-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0639069B1 (fr) | Forme galenique pour administration oculaire et procede de preparation | |
| LU87409A1 (fr) | Nouvelle forme cristalline de la ciclosporine,sa preparation et les compositions pharmaceutiques la contenant | |
| US11484516B2 (en) | Agents for increasing meibomian gland lipid secretion | |
| FR2573652A1 (fr) | Composition aqueuse de cromoglycate de sodium | |
| LU87613A1 (fr) | Nouvelles compositions opthalmiques a base d'une cyclosporine | |
| JP2020073591A (ja) | 局所粘膜用水性組成物 | |
| AU2005260090A1 (en) | Lubricant for the ocular surface | |
| EP0977550B1 (fr) | Utilisation d'au moins un extrait d'irvingia gabonensis dans un produit cosmetique et/ou pharmaceutique | |
| CA2443728C (fr) | Composition pharmaceutique a base de macrolides pour application locale en ophtalmologie | |
| LU84893A1 (fr) | Composition pharmaceutique | |
| EP1754491A1 (en) | Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist | |
| LU87161A1 (fr) | Compositions pharmaceutiques | |
| WO2011040432A1 (ja) | 洗眼剤 | |
| FR3131214A1 (fr) | Composition topique et son applicateur, destines a soulager le chalazion | |
| GB2122894A (en) | Ophthalmic ointment base | |
| FR2835748A1 (fr) | Composition ophtalmique sous forme d'emulsion | |
| JPH11217334A (ja) | 血中の中性脂質濃度低下剤 | |
| EP0433140B1 (fr) | Nouvelle préparation pharmaceutique anti-allergique à action prolongée | |
| BE682828A (cs) | ||
| WO2005034901A1 (fr) | Utilisation d’une combinaison d’acide cromoglicique et/ou d’un des sels et/ou esters et d’un agent gelifiant | |
| BE852947A (fr) | Filtration des rayons ultraviolets au moyen d'esters d'acides aminosalicycliques | |
| NO334330B1 (no) | Vannfritt hudpleiemiddel omfattende mikronisert urea, og fremgangsmåte for fremstilling av dette | |
| DK161737B (da) | Steril oejensalve og fremgangsmaade til fremstilling deraf | |
| FR2483778A1 (fr) | Composition ophtalmique contenant du 4'-(1-hydroxy-2-(isopropylamino)-ethyl)- methanesulfonanilide | |
| BE823375A (fr) | Medication ophtalmique solide |